touchREVIEWS in Oncology & Haematology – Volume 20, Issue 1 – 2024

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and reviews from esteemed experts who provide insights into novel therapies and their potential to change […]

Hepatocellular carcinoma (HCC) is the seventh most frequently occurring cancer in the world and the second most common cause of cancer mortality.1 The incidence of HCC has been growing rapidly, with a 75% increase in newly diagnosed cases from 1990 to 2015.2 Approximately 90% of HCC cases are associated with an underlying aetiology, most frequently chronic viral […]

Unmet clinical needs for patients with advanced epidermal growth factor receptor-mutated non–small-cell lung cancer Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have become the standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) harbouring a classical activating EGFR mutation (exon 19 deletion or exon 21 L858R). Osimertinib, a third-generation EGFR-TKI, is the […]

The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1 Platinum-based chemotherapy had long been the standard of care in patients with advanced or recurrent endometrial cancer. New approaches to the classification of endometrial cancer based […]

Cholangiocarcinoma (CCA) is a cancer of the epithelial cells lining the biliary tree in the liver and can occur both inside the liver (intrahepatic CCA [iCCA]) and outside the liver (extrahepatic CCA, which includes both perihilar and distal cholangiocarcinoma) (Figure 1). Figure 1: A diagram showing the anatomical locations of the different subtypes of biliary tract […]

Outcomes for patients with metastatic colorectal cancer have steadily improve due to discovery of new drugs as well as increasing number patients undergoing local therapies.1 Angiogenesis is of a paramount importance in this disease and since vascular endothelial growth factor (VEGF) discovery several drugs targeting this pathway have been developed.2,3 Fruquintinib (HMPL-013) is a tyrosine kinase […]

Key points Olutasidenib induces durable responses in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations in the phase I and II clinical trials. The side effects of olutasidenib are well known and highly manageable. Olutasidenib represents a therapeutic advance for these patients with a poor prognosis. Olutasidenib received the […]

Merkel cell carcinoma (MCC) is a rare, poorly differentiated and highly aggressive neuroendocrine cutaneous cancer with a high propensity to grow rapidly and metastasize early. Merkel cell polyomavirus (MCPyV) is now estimated to be the causative factor in up to 80% of MCC cases.1 Meanwhile, the remaining 20% are attributed to significant exposure to ultraviolet radiation.2 The […]

Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) designed to effectively deliver a potent topoisomerase I inhibitor (exatecan derivative) to HER2-expressing cancer cells and limit potential systemic toxicity.1 T-DXd has shown remarkable efficacy against recurrent HER2-positive breast cancer in many trials.2–5 This payload, an exatecan derivative, is highly active among camptothecins […]